LU77387A1 - - Google Patents

Info

Publication number
LU77387A1
LU77387A1 LU77387A LU77387A LU77387A1 LU 77387 A1 LU77387 A1 LU 77387A1 LU 77387 A LU77387 A LU 77387A LU 77387 A LU77387 A LU 77387A LU 77387 A1 LU77387 A1 LU 77387A1
Authority
LU
Luxembourg
Application number
LU77387A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of LU77387A1 publication Critical patent/LU77387A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
LU77387A 1976-05-24 1977-05-23 LU77387A1 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL7605526A NL7605526A (nl) 1976-05-24 1976-05-24 Nieuwe tetracyclische derivaten.

Publications (1)

Publication Number Publication Date
LU77387A1 true LU77387A1 (cg-RX-API-DMAC7.html) 1977-08-29

Family

ID=19826245

Family Applications (1)

Application Number Title Priority Date Filing Date
LU77387A LU77387A1 (cg-RX-API-DMAC7.html) 1976-05-24 1977-05-23

Country Status (18)

Country Link
US (1) US4145434A (cg-RX-API-DMAC7.html)
JP (2) JPS532465A (cg-RX-API-DMAC7.html)
AU (1) AU509073B2 (cg-RX-API-DMAC7.html)
BE (1) BE854915A (cg-RX-API-DMAC7.html)
CA (1) CA1122976A (cg-RX-API-DMAC7.html)
CH (2) CH633536A5 (cg-RX-API-DMAC7.html)
DE (2) DE2723209A1 (cg-RX-API-DMAC7.html)
DK (1) DK157868C (cg-RX-API-DMAC7.html)
ES (3) ES459024A1 (cg-RX-API-DMAC7.html)
FI (1) FI65238C (cg-RX-API-DMAC7.html)
FR (1) FR2352800A1 (cg-RX-API-DMAC7.html)
GB (1) GB1567862A (cg-RX-API-DMAC7.html)
HU (1) HU173795B (cg-RX-API-DMAC7.html)
IE (1) IE45419B1 (cg-RX-API-DMAC7.html)
LU (1) LU77387A1 (cg-RX-API-DMAC7.html)
NL (1) NL7605526A (cg-RX-API-DMAC7.html)
SE (1) SE436202B (cg-RX-API-DMAC7.html)
ZA (1) ZA772752B (cg-RX-API-DMAC7.html)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0007450A1 (de) * 1978-07-07 1980-02-06 Ciba-Geigy Ag Azatetracyclische Carbonitrile, ihre Herstellung, pharmazeutische Präparate, die diese enthalten und deren Verwendung
ATE9159T1 (de) * 1979-12-10 1984-09-15 Ciba-Geigy Ag Azatetracyclische carbonitrile.
FR2504140A1 (fr) * 1981-04-16 1982-10-22 Centre Nat Rech Scient Nouveaux derives tetracycliques de la dibenzazepine, leur procede de preparation et les compositions pharmaceutiques en renfermant
IL68711A (en) * 1982-05-18 1986-12-31 Sparamedica Ag Dihydro-8-halo-6-phenylpyrrolo-(3,4-d)(2)benzazepin derivatives,their preparation and pharmaceutical compositions containing them
JPS62101941U (cg-RX-API-DMAC7.html) * 1985-12-16 1987-06-29
IE62754B1 (en) * 1988-08-26 1995-02-22 Akzo Nv Tetracyclic antidepressants
EP0569096A1 (en) * 1992-05-08 1993-11-10 Akzo Nobel N.V. Depot preparation
ATE233765T1 (de) * 1993-04-06 2003-03-15 Abbott Lab Tetracyclische verbindungen als dopamin-agonisten
CA2182981C (en) * 1994-03-02 2006-10-17 Leonardus Petrus Carla Delbressine Sublingual or buccal pharmaceutical composition
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
US6057441A (en) * 1996-04-12 2000-05-02 Janssen Pharmaceutica, N.V. Substituted tetracyclic tetrahydrofuran derivatives
PL337027A1 (en) * 1997-05-26 2000-07-31 Akzo Nobel Nv Salts of aromatic sulphonic acids
HRP20020305A8 (en) * 2002-04-10 2009-03-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
HRP20020441A2 (en) * 2002-05-21 2003-12-31 Pliva D D 1-oxa-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
HRP20030160A2 (en) * 2003-03-06 2005-04-30 Pliva-Istra�iva�ki institut d.o.o. 1-thiadibenzoazulene derivatives and biological action thereof
AU2004237951A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
HRP20030885A2 (en) * 2003-11-03 2005-08-31 Pliva-Istra�iva�ki institut d.o.o. USE OF 2-THIA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYYTEM DISEASES AND DISORDERS
HRP20030956A2 (en) * 2003-11-21 2005-08-31 Pliva-Istra�iva�ki institut d.o.o. USE OF 1,2-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANU
HRP20030959A2 (cg-RX-API-DMAC7.html) * 2003-11-21 2005-10-31 Pliva-Istra�iva�ki institut d.o.o.
HRP20030954A2 (en) * 2003-11-21 2005-08-31 Pliva D.D. USE OF 1-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
HRP20030957A2 (en) * 2003-11-21 2005-08-31 Pliva-Istra�iva�ki institut d.o.o. USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
HRP20030953A2 (en) * 2003-11-21 2005-10-31 Pliva-Istra�iva�ki institut d.o.o. PREPARATION OF 1-AZA-2-OXA-DIBENZO[e,h]AZULENES AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
HRP20030955A2 (en) * 2003-11-21 2005-08-31 Pliva-Istra�iva�ki institut d.o.o. USE OF 1-OXADIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
HRP20030958A2 (en) * 2003-11-21 2005-08-31 Pliva-Istra�iva�ki institut d.o.o. USE OF 1,3-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
HRP20040104A2 (en) * 2004-01-30 2005-10-31 Pliva-Istra�iva�ki institut d.o.o. Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
RU2006129307A (ru) * 2004-02-13 2008-02-20 Пфайзер Продактс Инк. (Us) Терапевтические комбинации атипичных нейролептиков с антагонистами кортикотропин-рилизинг фактора
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
KR20070084123A (ko) * 2004-10-15 2007-08-24 엔.브이.오가논 양극성 장애 및 관련 증상의 치료
US7872147B2 (en) * 2005-04-07 2011-01-18 N. V. Organon Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
PT1917267E (pt) * 2005-04-07 2009-02-04 Organon Nv Forma cristalina de maleato de asenapina
PL1710241T3 (pl) * 2005-04-07 2010-04-30 Msd Oss Bv Związki pośrednie do wytwarzania trans-5-chloro-2-metylo-2,3,3a,12b-tetrahydro-1H-dibenz-[2,3:6,7]oksepino[4,5-c]pirolu
US7741358B2 (en) * 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
WO2007046554A1 (ja) * 2005-10-21 2007-04-26 Sumitomo Chemical Company, Limited ジベンゾオキセピノピロール化合物の製造方法、その中間体及び該中間体の製造方法
US7750167B2 (en) * 2006-07-05 2010-07-06 N.V. Organon Process for the preparation of asenapine and intermediate products used in said process
TW200817414A (en) * 2006-07-05 2008-04-16 Organon Nv Process for the preparation of asenapine and intermediate products used in said process
CA2667668A1 (en) * 2006-10-06 2008-04-10 N.V. Organon Amorphous asenapine and processes for preparing same
US7875729B2 (en) * 2007-01-05 2011-01-25 Synthon Bv Process for making asenapine
WO2008148515A1 (en) * 2007-06-05 2008-12-11 Synthon B.V. Intranasal administration of asenapine and pharmaceutical compositions therefor
JP5245428B2 (ja) * 2007-07-06 2013-07-24 住友化学株式会社 トランス−ジベンゾオキセノピロール化合物の製造方法およびその中間体
CN101918411A (zh) * 2008-01-04 2010-12-15 欧加农股份有限公司 一种制备阿塞那平的方法以及该方法中应用的中间体产物
WO2009104080A2 (en) 2008-02-20 2009-08-27 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
WO2009156889A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
AR077225A1 (es) 2009-06-24 2011-08-10 Organon Nv Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza
AR077429A1 (es) 2009-07-29 2011-08-24 Organon Nv Compuestos hidroxiasenapina sus derivados y composiciones farmaceuticas que comprenden los mismos
US8779161B2 (en) 2010-06-18 2014-07-15 Dr. Reddy's Laboratories Limited Asenapine maleate
JP5815702B2 (ja) 2010-07-29 2015-11-17 ラボラトリオス レスヴィ，エス．エル． アセナピンの新規な製造方法
CA2818025A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2012066565A2 (en) 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
ES2575544T3 (es) 2010-12-24 2016-06-29 Medichem, S.A. Procedimientos para la preparación de 5-cloro-2-metil-2,3,3a,12b-tetrahidro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pirrol
WO2012123325A1 (en) 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
ITMI20110734A1 (it) 2011-05-02 2012-11-03 Olon Spa Sali cristallini di asenapina
EP2524921A1 (en) * 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Salts of Asenapine
EP2524919A1 (en) * 2011-05-17 2012-11-21 Sandoz AG Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
EP2709615A1 (en) 2011-05-18 2014-03-26 Laboratorios Lesvi, S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
US9505771B2 (en) 2011-05-18 2016-11-29 Laboratories Lesvi S.L. Stable micronised monoclin form of asenapine maleate and its synthesis
WO2013024492A2 (en) 2011-07-01 2013-02-21 Megafine Pharma (P) Ltd. A process for the preparation of asenapine and novel salts thereof
WO2013011461A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of asenapine maleate
WO2013035109A1 (en) 2011-09-08 2013-03-14 Mylan Laboratories Ltd Improved process for the preparation of asenapine maleate
EP2572703A1 (en) 2011-09-21 2013-03-27 Hexal AG Compressed oral dosage form for asenapine maleate
WO2013041604A1 (en) 2011-09-21 2013-03-28 Sandoz Ag Crystal form of asenapine maleate
WO2013080069A1 (en) 2011-11-28 2013-06-06 Ranbaxy Laboratories Limited Process for the preparation of asenapine intermediate
CN103254201B (zh) * 2012-02-21 2016-04-13 四川科伦药物研究有限公司 一种阿塞那平的制备方法
WO2013190481A1 (en) * 2012-06-21 2013-12-27 Alembic Pharmaceuticals Limited Process for preparing asenapine and salts of intermediates thereof
ITMI20121810A1 (it) 2012-10-24 2014-04-25 Chemo Iberica Sa Poliformi di maleato di asenapina e processo per la loro preparazione
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014127786A1 (en) 2013-02-22 2014-08-28 Zentiva, K.S. Orally disintegrating pharmaceutical composition comprising asenapine
CN103113379A (zh) * 2013-03-12 2013-05-22 盛世泰科生物医药技术(苏州)有限公司 阿塞那平马来酸盐的合成工艺
CN103351393B (zh) * 2013-07-03 2016-04-06 华裕(无锡)制药有限公司 用于制备阿森那平之还原剂及阿森那平之制备方法
EP4032889A1 (en) 2013-12-20 2022-07-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN103772401A (zh) * 2014-01-07 2014-05-07 万特制药(海南)有限公司 11-氯-2,3,3a,12b-四氢-2-甲基-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯-1-酮的一种新精制方法
CN103772400A (zh) * 2014-01-07 2014-05-07 万特制药(海南)有限公司 反式-5-氯-2,3,3a,12b-四氢-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯的制备方法
WO2016198113A1 (en) 2015-06-11 2016-12-15 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
CA2990004C (en) 2015-06-19 2024-04-23 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio, Inc. derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
RU2764443C2 (ru) 2016-12-20 2022-01-17 Лтс Ломанн Терапи-Систем Аг Трансдермальная терапевтическая система, содержащая азенапин и полисилоксан или полиизобутилен
WO2018115001A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN110799180A (zh) 2017-06-26 2020-02-14 罗曼治疗系统股份公司 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统
AU2019288382B2 (en) 2018-06-19 2024-07-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN110183457A (zh) * 2019-06-27 2019-08-30 浙江天顺药业有限公司 一种阿塞那平及其制备方法
CN110606852B (zh) 2019-08-13 2021-02-05 浙江奥翔药业股份有限公司 制备阿塞那平的方法
US11679407B2 (en) * 2020-06-26 2023-06-20 Intel Corporation Liquid metal thermal interface material application
WO2023006954A1 (en) 2021-07-30 2023-02-02 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Asenapine for use in cancer
AU2023324882A1 (en) 2022-08-19 2025-03-20 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH501007A (de) * 1968-11-27 1970-12-31 Ciba Geigy Ag Verfahren zur Herstellung von neuen Thiepin- und Oxepinderivaten
NL178593C (nl) * 1974-01-31 1986-04-16 Akzo Nv Werkwijze ter bereiding van een farmaceutisch preparaat op basis van een tetracyclische verbinding en werkwijze voor de bereiding van de daarbij te gebruiken tetracyclische verbindingen.
AU469026B2 (en) * 1974-11-07 1976-01-29 Ciba-Geigy Ag New azepine derivatives and process forthe production thereof

Also Published As

Publication number Publication date
US4145434A (en) 1979-03-20
DE2723209A1 (de) 1977-12-15
SE436202B (sv) 1984-11-19
FI65238C (fi) 1984-04-10
DK157868B (da) 1990-02-26
FR2352800A1 (fr) 1977-12-23
SE7705957L (sv) 1977-11-25
DK157868C (da) 1990-07-30
GB1567862A (en) 1980-05-21
BE854915A (fr) 1977-11-23
DE2760372C2 (cg-RX-API-DMAC7.html) 1991-05-29
JPS532465A (en) 1978-01-11
CH637382A5 (de) 1983-07-29
DK227477A (da) 1977-11-25
NL7605526A (nl) 1977-11-28
JPS6238348B2 (cg-RX-API-DMAC7.html) 1987-08-17
HU173795B (hu) 1979-08-28
IE45419B1 (en) 1982-08-25
ES470408A1 (es) 1979-01-01
AU509073B2 (en) 1980-04-17
IE45419L (en) 1977-11-24
CH633536A5 (de) 1982-12-15
JPS61178965A (ja) 1986-08-11
ZA772752B (en) 1978-04-26
JPS6134426B2 (cg-RX-API-DMAC7.html) 1986-08-07
AU2533177A (en) 1978-11-23
FI771635A7 (cg-RX-API-DMAC7.html) 1977-11-25
CA1122976A (en) 1982-05-04
ES470407A1 (es) 1979-01-01
FR2352800B1 (cg-RX-API-DMAC7.html) 1980-02-01
ES459024A1 (es) 1978-11-01
FI65238B (fi) 1983-12-30

Similar Documents

Publication Publication Date Title
FR2352800B1 (cg-RX-API-DMAC7.html)
JPS573259Y2 (cg-RX-API-DMAC7.html)
FR2370095B1 (cg-RX-API-DMAC7.html)
DK111276A (cg-RX-API-DMAC7.html)
JPS5511991B2 (cg-RX-API-DMAC7.html)
JPS5715482Y2 (cg-RX-API-DMAC7.html)
JPS52165168U (cg-RX-API-DMAC7.html)
JPS5647408Y2 (cg-RX-API-DMAC7.html)
DK136987C (cg-RX-API-DMAC7.html)
DK138827C (cg-RX-API-DMAC7.html)
JPS5324519B1 (cg-RX-API-DMAC7.html)
JPS52110840U (cg-RX-API-DMAC7.html)
JPS52109951U (cg-RX-API-DMAC7.html)
JPS5344966U (cg-RX-API-DMAC7.html)
JPS5394284U (cg-RX-API-DMAC7.html)
JPS532787U (cg-RX-API-DMAC7.html)
JPS531626U (cg-RX-API-DMAC7.html)
JPS5389886U (cg-RX-API-DMAC7.html)
JPS52161449U (cg-RX-API-DMAC7.html)
JPS52160515U (cg-RX-API-DMAC7.html)
DK21077A (cg-RX-API-DMAC7.html)
JPS52138037U (cg-RX-API-DMAC7.html)
JPS5394189U (cg-RX-API-DMAC7.html)
CH604195A5 (cg-RX-API-DMAC7.html)
DD126301A5 (cg-RX-API-DMAC7.html)